GlassScriptPhysician profile
Nicholas Noyce
NPI 1013612829
$3,110.87
in general payments reported to CMS, 2019-2025
20 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $762 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $430.12 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $285.01 | 2025 | Nemluvio |
| Abbvie INC. | $271.76 | 2024-2025 | |
| Lilly USA, LLC | $248.57 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $229.07 | 2025 | Tremfya |
| Ucb, INC. | $194.77 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $180.55 | 2025 | Tremfya |
| Incyte Corporation | $179.28 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $165.23 | 2025 | |
| Novartis Pharmaceuticals Corporation | $158.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $154.56 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $120.94 | 2024-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $108.79 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Biofrontera INC. | $85.94 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.49 | 2025 | |
| Amgen INC. | $51.01 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $47.69 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.25 | 2024 | Spevigo |
| Genentech USA, INC. | $16.63 | 2024 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Noyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.